Seeking Alpha


Send Message
View as an RSS Feed
View Goodguy's Comments BY TICKER:

Latest  |  Highest rated
  • Deeper Research: The Commercial Potential Of Belviq [View instapost]
    Thanks much Moral.
    Dec 16, 2013. 12:25 AM | Likes Like |Link to Comment
  • Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology [View article]
    Dec 9, 2013. 10:41 PM | Likes Like |Link to Comment
  • Arena's Lorcaserin: What Now? [View article]
    I'm in total agreement with XRTrader: the rat data is a non-issue for humans from a scientific standpoint, and obesity has a huge effect on morbidity and cost of medical care in this country. Lorcaserin will help reduce health insurance premiums for each commenter here, and for all Americans, year after year after year.
    Sep 20, 2010. 01:46 AM | 1 Like Like |Link to Comment
  • Is Arena’s Lorcaserin More Valuable Than Dendreon’s Provenge? [View article]
    Phillydan, I wholeheartedly agree with the latter half of your second paragraph......something seems odd about that placebo-group data.
    Jun 7, 2010. 08:06 PM | Likes Like |Link to Comment
  • Investing in the Obesity Drug Basket [View article]
    The difference for Qnexa may be the 500 calorie deficit. If I read Mr. Murphy's table correctly: if the other protocols didn't specify that the patient achieve a 500cal per day deficit via exercise or lowered intake or some combination, the Qnexa trial theoretically should be ahead of the others by a loss of 56/lbs avg per participant over the course of their trial, even without using the drug. This is the calculation-->>> -500 cal/day X 392 days = -196,000 cal/ (3500 cal per pound of fat) = -56lbs. . So in the Qnexa trial if the protocol was followed, even without the drug a 56 lb weight loss should have resulted on average per person.

    Nice balanced analysis Mr. Murphy. All three companies should have a good run.
    Disclosure: Long VVUS, ARNA
    Sep 24, 2009. 10:55 PM | 2 Likes Like |Link to Comment
  • Electro-Optical Sciences: A Speculative Stock with Great Potential [View article]
    I couldn't agree more. Check their web site for more information on how effective the MelaFind device is.

    Disclosure: Long MELA
    Jul 8, 2009. 05:05 PM | 1 Like Like |Link to Comment